Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $26.40 +0.04%
EPS Growth %: -52.4%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -52.4%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Increasing unusual option volume: UTHR ABUS OPRA GFL ACAD
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
- Dave & Buster's Entertainment (PLAY) Misses Q2 EPS by 46c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
